Market closedNon-fractional
Poseida Therapeutics/PSTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Poseida Therapeutics
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Ticker
PSTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
335
Website
poseida.com
PSTX Metrics
BasicAdvanced
$350M
Market cap
-
P/E ratio
-$1.18
EPS
0.53
Beta
-
Dividend rate
Price and volume
Market cap
$350M
Beta
0.53
Financial strength
Current ratio
2.557
Quick ratio
2.485
Long term debt to equity
92.874
Total debt to equity
99.961
Interest coverage (TTM)
-12.88%
Management effectiveness
Return on assets (TTM)
-24.85%
Return on equity (TTM)
-89.91%
Valuation
Price to revenue (TTM)
4.053
Price to book
4.13
Price to tangible book (TTM)
4.42
Price to free cash flow (TTM)
-4.663
Growth
Revenue change (TTM)
-40.82%
Earnings per share change (TTM)
104.41%
3-year earnings per share growth (CAGR)
-25.91%
What the Analysts think about PSTX
Analyst Ratings
Majority rating from 5 analysts.
PSTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$28M
12.85%
Net income
-$24M
-4.35%
Profit margin
-86.12%
-15.24%
PSTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.32
-$0.35
-$0.27
-$0.25
-
Expected
-$0.53
-$0.29
-$0.39
-$0.42
-$0.41
Surprise
-39.39%
19.66%
-30.05%
-40.48%
-
PSTX News
AllArticlesVideos
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
PRNewsWire·4 weeks ago
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
PRNewsWire·2 months ago
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
PRNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Poseida Therapeutics stock?
Poseida Therapeutics (PSTX) has a market cap of $350M as of July 27, 2024.
What is the P/E ratio for Poseida Therapeutics stock?
The price to earnings (P/E) ratio for Poseida Therapeutics (PSTX) stock is 0 as of July 27, 2024.
Does Poseida Therapeutics stock pay dividends?
No, Poseida Therapeutics (PSTX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Poseida Therapeutics dividend payment date?
Poseida Therapeutics (PSTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Poseida Therapeutics?
Poseida Therapeutics (PSTX) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Poseida Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.